Huntington’s

A biotech firm which is aiming to slow down the neurodegeneration process in Huntington's has completed a £35m funding round to support is drug development work. LoQus23 Therapeutics is investigating small molecule drugs that could stop DNA instability and slow disease progression in Huntington's Disease, as well as myotonic dystrophy type 1 and similar triplet [...]